Health Care [ 9/12 ] | Biotechnology [ 37/73 ]
NASDAQ | Common Stock
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 25 | -0.51 Increased by +5.56% | -0.38 Decreased by -34.21% |
| May 6, 25 | -0.36 Increased by +35.71% | -0.55 Increased by +34.55% |
| Mar 10, 25 | -0.51 Decreased by -4.08% | 0.17 Decreased by -394.46% |
| Nov 5, 24 | -0.60 Decreased by -25.00% | -0.58 Decreased by -3.45% |
| Aug 6, 24 | -0.54 Decreased by -10.20% | -0.55 Increased by +1.82% |
| May 8, 24 | -0.56 Increased by +20.00% | -0.55 Decreased by -1.82% |
| Mar 11, 24 | -0.49 Increased by +24.62% | -0.48 Decreased by -2.08% |
| Nov 7, 23 | -0.48 Increased by +15.79% | -0.51 Increased by +5.88% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -43.78 M Decreased by -44.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -30.39 M Increased by +1.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 364.00 K Decreased by -80.68% | -33.57 M Decreased by -25.38% | Decreased by -9.22 K% Decreased by -548.95% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -34.55 M Decreased by -60.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -30.38 M Decreased by -51.19% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -30.97 M Decreased by -14.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.88 M Increased by +N/A% | -26.77 M Decreased by -6.50% | Decreased by -1.42 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -21.50 M Increased by +3.22% | Decreased by N/A% Decreased by N/A% |